Engineered immune cells take on Hard-to-Treat liver cancer
NCT ID NCT06757881
First seen Jan 11, 2026 · Last updated May 20, 2026 · Updated 25 times
Summary
This early-phase study tests a new treatment for people with advanced liver cancer that has not responded to standard therapies. The treatment uses the patient's own immune cells, modified to target a protein called IL1RAP on cancer cells. The main goals are to check safety and find the right dose, with only 3 participants enrolled so far.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.